ArticleJournal of the West African College of Surgeons
Mooren'S ulcer in ibadan, southwest Nigeria.
Article in Journal of the West African College of Surgeons. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Mooren's ulcer: a multifactorial autoimmune peripheral ulcerative keratitis and current treatment protocols.Frontiers in medicine · 2025Review
- Surgical Management of Peripheral Ulcerative Keratitis: Update on Surgical Techniques and Their Outcome.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Surgical treatment of peripheral ulcerative keratitis and necrotizing scleritis in granulomatosis with polyangiitis.Saudi medical journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMooren's ulcer has been described as an idiopathic, painful, relentless, peripheral, chronic ulcerative keratitis that progresses circumferentially and centrally, with an unusual geographical presentation and distribution.
aimTo review the demographic and clinical characteristics of patients with Mooren's ulcer at University College Hospital, Ibadan, Nigeria over seven years, and, the outcome of treatment. STUDY
designA retrospective case series.
methodsMedical records of all patients with Mooren's ulcer seen in the Eye Clinic, University College Hospital, Ibadan, South-west Nigeria between January 2007 and December 2013 were reviewed.
resultsThirty-one eyes of 23 patients, (18 males, overall mean age of all patients 30.9 ±16.6 years) were affected with Mooren's ulcer. The right eye was involved in nine (39.1%) patients while eight (34.8%) patients had bilateral lesions. Most common presenting symptoms were redness and pain, with an average of 6.8 clock hour-limbal involvement. All patients received topical and systemic steroids, while eight patients with severe disease, or poor response to treatment with steroids, received systemic methotrexate or cyclophosphamide. Surgical treatment with conjunctivectomy and cryotherapy was undertaken in 14 (60.9%) patients (21 eyes) who had a minimum follow-up period of eight weeks, while those presenting with perforation also had scleral patch graft or direct repair. The ulcer healed with varying degrees of corneal opacity in 18 (85.7%) of the 21 eyes, while the remaining three eyes developed descemetocele, anterior staphyloma or corneal perforation. Large proportion (76.2%) of eyes maintained their presenting acuity.
conclusionMooren's ulcer remains an uncommon disease in Ibadan, South-west Nigeria, and the clinical presentation is as recorded in other parts of the West African sub-region. Systemic immunosuppression with methotrexate and scleral patch graft appear to give good outcome in patients presenting with severe ulceration and/or perforation.
Indexed as
Identifiers
25717466PMC4337214W2436407988What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.